Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM314CZ)

• Drug Name: REV-598 Drug Info
• Synonyms: EV-598

Indication

Disease Entry	ICD 11	Status	REF
Carcinoid syndrome	5B10	Terminated	[1]

• Cross-matching ID: TTD Drug ID: DM314CZ

Molecule-Related Drug Atlas

Drug(s) Targeting Histamine receptor (HR)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Histamine Phosphate	DMV7IM6	Diagnostic imaging	N.A.	Approved	[3]
Repirinast	DM6KI0D	Asthma	CA23	Approved	[4]
Levomequitazine	DMAYC76	Seasonal allergic rhinitis	CA08.01	Phase 3	[5]
ETX-9101	DMZOA2L	Asthma	CA23	Phase 2	[6]
LCB-2183	DMY4IWC	Asthma	CA23	Phase 2	[7]
ETS-6218	DMV96BY	Fibromyalgia	MG30.01	Phase 2	[6]
Votucalis	DMW4LTI	Allergic rhinitis	CA08.0	Phase 2	[8]
OX-NLA	DMPEHBJ	Allergic rhinitis	CA08.0	Discontinued in Phase 3	[9]
Tesmilifene	DMPB36I	Breast cancer	2C60-2C65	Discontinued in Phase 2	[10]
CP-118	DMNJD9H	Allergic rhinitis	CA08.0	Discontinued in Phase 2	[11]

Drug(s) Targeting 5-HT receptor (5HTR)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Metergolin	DMJFP6G	Hyperprolactinaemia	5A60.1	Approved	[12]
Paliperidone	DM7NPJS	Psychotic disorder	6A20-6A25	Approved	[13]
Ramosetron	DMH7GN8	Diarrhea-predominant irritable bowel syndrome	DD91.01	Approved	[12]
Pizotyline	DMV74ZH	Headache	8A80-8A84	Approved	[13]
Tandospirone	DMPHWU6	Anxiety disorder	6B00-6B0Z	Approved	[12]
Nafronyl	DMVMQ1L	Cerebrovascular ischaemia	8B1Z	Approved	[13]
ITI-007	DMUQ1DO	Depression	6A70-6A7Z	Phase 3	[14]
Fenfluramine	DM0762O	Dravet syndrome	8A61.11	Phase 3	[15]
MIN-117	DMSLIW6	Major depressive disorder	6A70.3	Phase 2	[14]
Lu-AA34893	DM2ZUXK	Anxiety disorder	6B00-6B0Z	Phase 2	[16]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
5-HT receptor (5HTR)	TT85JO3	NOUNIPROTAC	Inhibitor	[2]
Histamine receptor (HR)	TT7CXIM	NOUNIPROTAC	Inhibitor	[2]

References

• [1] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800016819)
• [2] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800016819)
• [3] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [4] Mechanism of action of MY-1250, an active metabolite of Repirinast, in inhibiting histamine release from rat mast cells. Br J Pharmacol. 1992 Mar;105(3):587-90.
• [5] Oxidation of histamine H1 antagonist mequitazine is catalyzed by cytochrome P450 2D6 in human liver microsomes. J Pharmacol Exp Ther. 1998 Feb;284(2):437-42.
• [6] Clinical pipeline report, company report or official report of e-Therapeutics.
• [7] LCB 2183 inhibits the inflammation associated with oxazolone-induced contact sensitivity. Int J Immunopharmacol. 1994 Aug;16(8):675-83.
• [8] CA patent application no. 520580, Histamine binding compounds for treatment method for disease conditions mediated by neutrophils.
• [9] Clinical pipeline report, company report or official report of Orexo.
• [10] Effects of tesmilifene, a substrate of CYP3A and an inhibitor of P-glycoprotein, on the pharmacokinetics of intravenous and oral docetaxel in rats. J Pharm Pharmacol. 2010 Aug;62(8):1084-8.
• [11] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800025139)
• [12] Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77.
• [13] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [14] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [15] Pharmacotherapy for obesity. Drugs. 2005;65(10):1391-418.
• [16] Encyclopedia of Psychopharmacology. Ian Stolerman. 2010. Page(105).